FIELD: medicine.
SUBSTANCE: present invention relates to combined therapy with {3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4difluorophenyl} amide of propane-1-sulphonic acid (compound 1) or its pharmaceutically acceptable salt and EGFR inhibitor, selected from erlotinib and cetuximab, for treating cancer, containing b-Raf with V600 mutation, namely colorectal cancer, melanoma and thyroid cancer.
EFFECT: combination of compound 1 with EGFR inhibitor leads to improved anti-tumor effects, which considerably exceed the results, obtained for each compound separately, without increasing the toxicity.
20 cl, 6 ex, 15 tbl, 9 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINED THERAPY INCLUDING VEMURAFENIB AND INTERFERON, FOR USE IN TREATING CANCER | 2011 |
|
RU2592983C2 |
| PHARMACEUTICAL COMBINATIONS | 2017 |
|
RU2759669C2 |
| METHOD FOR ANTITUMOUR AGENT INTRODUCTION | 2013 |
|
RU2638795C2 |
| COMBINATION THERAPY | 2018 |
|
RU2815400C2 |
| COMBINATIONS (COMPOSITIONS), INCLUDING DMXAA FOR CANCER TREATMENT | 2006 |
|
RU2404765C2 |
| CO-CRYSTALS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | 2014 |
|
RU2675270C2 |
| CO-CRYSTALS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEREOF | 2014 |
|
RU2823603C2 |
| THERAPEUTIC COMBINATIONS CONTAINING RAF INHIBITOR AND ERK INHIBITOR | 2017 |
|
RU2774612C2 |
| USE OF 2-CARBOXAMIDE-CYCLOAMINO UREA DERIVATIVES IN TREATMENT OF EGFR-DEPENDENT DISEASES OR DISEASES WITH ACQUIRED RESISTANCE TO AGENTS TARGETED AT EGFR-FAMILY MEMBERS | 2011 |
|
RU2589695C2 |
| METHODS OF TREATING PANCREATIC CANCER | 2011 |
|
RU2576609C2 |
